Quantum Biopharma (QNTM) Equity Average (2024 - 2026)

Quantum Biopharma has disclosed Equity Average across 3 years of filings, most recently posting $3.8 million for Q1 2026.

• Equity Average for Q1 2026 came in at $3.8 million, down 56.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (down 56.31% YoY), and the FY2025 annual result was $9.2 million, changed N/A from the prior year.
• Equity Average came in at $3.8 million for Q1 2026 at Quantum Biopharma, down from $7.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $13.9 million in Q4 2024 to a low of $3.8 million in Q1 2026.
• The 3-year median for Equity Average is $7.8 million (2025), against an average of $8.4 million.
• Across the five-year window, Equity Average tumbled 43.91% in 2025 and plunged 56.31% in 2026, its largest moves.
• Quantum Biopharma's Equity Average stood at $13.9 million in 2024, then sank by 43.91% to $7.8 million in 2025, then sank by 51.72% to $3.8 million in 2026.
• The last three Equity Average figures came in at $3.8 million (Q1 2026), $7.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.